LBX Pharmacy Chain JSC
SSE:603883
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
LBX Pharmacy Chain JSC
Note Receivable
LBX Pharmacy Chain JSC
Note Receivable Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Note Receivable | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
LBX Pharmacy Chain JSC
SSE:603883
|
Note Receivable
¥61m
|
CAGR 3-Years
-7%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
11%
|
|
|
D
|
DaShenLin Pharmaceutical Group Co Ltd
SSE:603233
|
Note Receivable
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Yifeng Pharmacy Chain Co Ltd
SSE:603939
|
Note Receivable
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
ShuYu Civilian Pharmacy Corp Ltd
SZSE:301017
|
Note Receivable
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Yixintang Pharmaceutical Group Co Ltd
SZSE:002727
|
Note Receivable
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
A
|
Anhui Huaren Health Pharmaceutical Co Ltd
SZSE:301408
|
Note Receivable
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
LBX Pharmacy Chain JSC
Glance View
LBX Pharmacy Chain JSC has emerged as a significant player in the pharmaceutical retail sector in China, riding the wave of increasing health consciousness and the aging population. Founded in a fast-paced, constantly evolving market, the company has strategically positioned itself to leverage this demographic shift. Its primary business model revolves around operating an extensive network of pharmacy outlets that serve both urban and rural customers. By offering a wide range of products, from prescription medications to health supplements and wellness goods, LBX ensures it caters to a diverse clientele, satisfying varying health care needs. The implementation of an omnichannel approach, integrating online and offline sales, has not only enhanced customer convenience but also expanded its reach, reinforcing its market position. Central to LBX’s profitability is its efficient supply chain management and strategic location of stores in high-traffic areas, which augments its accessibility and stock management capabilities. The company leverages partnerships with leading pharmaceutical manufacturers and distributors, securing competitive pricing and product availability. Additionally, its investment in technology bolsters its operational efficiency, enabling real-time inventory tracking and personalized customer service. This tech-driven approach enhances customer loyalty and provides insights into consumer behavior, guiding strategic decisions. Through a well-crafted blend of traditional retail expertise and innovative solutions, LBX Pharmacy Chain JSC continues to solidify its foothold in the market, driving revenue growth and expanding its reach across China.
See Also
What is LBX Pharmacy Chain JSC's Note Receivable?
Note Receivable
61m
CNY
Based on the financial report for Sep 30, 2025, LBX Pharmacy Chain JSC's Note Receivable amounts to 61m CNY.
What is LBX Pharmacy Chain JSC's Note Receivable growth rate?
Note Receivable CAGR 10Y
11%
Over the last year, the Note Receivable growth was -31%. The average annual Note Receivable growth rates for LBX Pharmacy Chain JSC have been -7% over the past three years , -2% over the past five years , and 11% over the past ten years .